27 October 2017Big Pharma

Teva suffers defeat as Copaxone claims invalidated

The English High Court has invalidated two patent claims protecting Copaxone (glatiramer acetate), a billion-dollar drug marketed by Teva.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Teva drops Copaxone generic suit against Mylan

12 December 2017 Teva has dropped its litigation over two US patents against Mylan, after a district court adopted Mylan’s interpretation of the patents.

Americas

Teva to appeal against invalidation of Copaxone patents

31 January 2017 Teva will appeal against a decision which saw the invalidation of four patents covering its multiple sclerosis drug Copaxone.

Big Pharma

Teva survives Copaxone patent challenge

22 May 2015 Teva has successfully defended two patents related to its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate) at the English High Court.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Teva suffers defeat as Copaxone claims invalidated

More on this story

Editor's picks

Editor's picks

More features